Advertisement

Topics

Eli Lilly Builds Upon Body Of Clinical Evidence For CYRAMZA (Ramucirumab) With Phase III RANGE Data Demonstrating Superior Progression-Free Survival In Advanced Or Metastatic Urothelial Cancer

20:00 EDT 10 Sep 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Eli Lilly Builds Upon Body Of Clinical Evidence For CYRAMZA (Ramucirumab) With Phase III RANGE Data Demonstrating Superior Progression-Free Survival In Advanced Or Metastatic Urothelial Cancer

NEXT ARTICLE

More From BioPortfolio on "Eli Lilly Builds Upon Body Of Clinical Evidence For CYRAMZA (Ramucirumab) With Phase III RANGE Data Demonstrating Superior Progression-Free Survival In Advanced Or Metastatic Urothelial Cancer"

Quick Search
Advertisement